Phase I Clinical Study to Evaluate the Safety and Efficacy of SSGJ-706 Monotherapy for Patients With Advanced Solid Tumors

Phase I Clinical Study to Evaluate the Safety, Tolerability, and Initial Efficacy of SSGJ-706 Monotherapy for Patients With Advanced Solid Tumors

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06533605

Enrollment

Registered

2024-08-01

Start date

2024-08-31

Completion date

2025-08-31

Last updated

2024-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Solid Tumors Patients

Keywords

Solid Tumors

Brief summary

This study includes two parts, different part has different administration frequencies of SSGJ-706.

Detailed description

This study is a study of SSGJ-706 monotherapy in advanced Solid Tumors. This study includes two parts, different part has different administration frequencies of SSGJ-706. Part A is QW and part B is Q3W. Each part will assess the efficacy and safety of the preset several dose levels of SSGJ-706 in advanced Solid Tumors.

Interventions

DRUGSSGJ-706

Bispecific antibody

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

1. Males and/or females over age 18 2. Histologically and/or cytologically documented advanced or metastatic Solid Tumors . 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 4. Expected survival \>=3 months. 5. Signed informed consent form.

Exclusion criteria

1. Known uncontrolled or symptomatic central nervous system metastatic disease. 2. Adverse events (with exception of alopecia and fatigue) from any prior anticancer therapy of grade \>1 (National Cancer Institute Common terminology Criteria \[NCI CTCAE\] v.5.0). 3. Inadequate organ or bone marrow function. 4. Pregnant or breast-feeding woman. 5. Known allergies, hypersensitivity, or intolerance to SSGJ-706 The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Design outcomes

Primary

Measure	Time frame	Description
DLTs	12 months	Dose limiting toxicity
MTD or MAD	12 months	maximum tolerated dose or the maximum administered dose if MTD is not reached

Secondary

Measure	Time frame	Description
The blood concentration of SSGJ-706	12 months	PK characteristics

Contacts

Primary ContactHao Chen, MD, Ph.D

chenhao3996913@163.com15009467790

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026